The Relationship of the Fibrinogen Cleavage Biomarker Aa-Val360 With Disease Severity and Activity in α1-Antitrypsin Deficiency

In cross-sectional studies, Aa-Val360 reflects disease severity in AATD and may be a useful marker of disease activity in patients with early disease in whom therapeutic intervention may be indicated.